The JUN Knockout 769-P Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population of the human 769-P renal cell carcinoma line, featuring targeted disruption of the JUN gene. This heterogeneous cell pool serves as a robust loss-of-function model for investigating c-Jun transcription factor biology, avoiding clonal selection bias and maintaining genetic diversity relevant to tumor heterogeneity.
The parental 769-P cell line originates from a human clear cell renal cell carcinoma (ccRCC) and displays epithelial morphology characteristic of kidney tumor cells. It is a standard model for studying ccRCC pathophysiology, including signaling networks driving oncogenesis, metabolic reprogramming, and drug resistance, providing a clinically pertinent background for gene knockout studies.
c-Jun, encoded by JUN, is a bZIP transcription factor and central component of the AP-1 complex. Its activation is predominantly mediated by JNK1/2 or ERK1/2 phosphorylation at Ser63 and Ser73, which promotes heterodimerization with partners such as c-Fos, ATF2, MAF, and subsequent binding to AP-1/TRE cis-regulatory elements. This leads to transcriptional control of genes essential for cell cycle progression (Cyclin D1), apoptosis inhibition (Bcl-2), extracellular matrix degradation (MMP-1, MMP-9), and angiogenesis (VEGF). Upstream receptors and kinases, including RTKs activated by EGF and PDGF, propagate signals via the Ras-Raf-MEK-ERK cascade, while stress stimuli and inflammatory cytokines like TNF-?? and IL-1 converge on MAP3K-MAP2K-JNK axes. Additionally, c-Jun interfaces with Wnt and TGF-?? pathways through interactions with TCF and the coactivator CBP/p300, further expanding its regulatory reach.
In the 769-P ccRCC context, loss of JUN provides a means to mechanistically dissect AP-1-dependent oncogenic processes. c-Jun overexpression and hyperactivity are associated with enhanced proliferation, migration, and resistance to apoptosis in renal carcinoma. The polyclonal knockout model allows evaluation of JUN’s contribution to these aggressive traits without clonal biases, and it enables assessment of c-Jun’s interplay with other hallmark ccRCC drivers, such as dysregulated HIF and mTOR signaling.
Typical experimental applications include immunoblotting for total and phosphorylated c-Jun, RT-qPCR quantification of downstream AP-1 targets (e.g., Cyclin D1, MMP-9), cell viability (MTS) and apoptosis (Annexin V) assays, transwell migration/invasion studies, AP-1 luciferase reporter gene assays, ChIP-qPCR for JUN promoter occupancy, transcriptome-wide RNA-seq, and high-throughput drug sensitivity profiling. This product is well suited for functional genomics, signal transduction research, and therapeutic targeting studies in ccRCC. For further information, please contact Ascent Research.
